关于《PARP抑制剂相关性骨髓异常增生综合征和急性髓细胞性白血病：随机对照试验的安全性荟萃分析和WHO药物警戒数据库的回顾性研究》的解读Interpretation of Myelodysplastic syndrome and acute myeloidleukaemia in patients treated with PARP inhibitors:a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
曾靖;尹如铁;
摘要(Abstract)：
多腺苷二磷酸核糖聚合酶[poly(ADP-ribose) polymerase,PARP]抑制剂在多个瘤种,特别是卵巢癌中显示出确切的有效性和可靠的安全性。然而,一些罕见和迟发的不良事件,包括骨髓异常增生综合征(myelodysplastic syndrome,MDS)和急性髓细胞性白血病(acute myelogenous leukemia,AML)病例的出现提示研究者和临床医生必须提高警惕。由于此类不良反应发生率低,Morice等通过系统回顾和安全性荟萃分析,以评估与PARP抑制剂相关的MDS和AML的发生风险和发病率。并通过对世界卫生组织药物警戒数据库(VigiBase)进行分析,了解与PARP抑制剂相关的MDS和AML病例的临床特征。笔者对该研究进行了解读,以帮助临床医生更好地了解PARP抑制剂迟发性血液毒性并及时识别与处理。
关键词(KeyWords)： PARP抑制剂;骨髓异常增生综合征;急性髓细胞性白血病
基金项目(Foundation):
作者(Authors): 曾靖;尹如铁;
参考文献(References)：
- [1]MATEO J,LORD C J,SERRA V,et al.A decade of clinical development of PARP inhibitors in perspective[J].Ann Oncol,2019,30(9):1437-1447.
- [2]RUSCITO I,BELLATI F,RAY-COQUARD I,et al.Incorpor-ating Parp-inhibitors in Primary and Recurrent Ovarian Cancer:A Meta-analysis of 12 phase Ⅱ/Ⅲ randomized controlled trials[J].Cancer Treat Rev,2020,87:102040.
- [3]LAFARGUE C J,DAL MOLIN G Z,SOOD A K,et al.Exploring and comparing adverse events between PARP inhib-itors[J].Lancet Oncol,2019,20(1):e15-e28.
- [4]MIRZA M R,MONK B J,HERRSTEDT J,et al.Niraparib Maintenance Therapy in Platinum-Sensitive,Recurrent Ovarian Cancer[J].N Engl J Med,2016,375(22):2154-2164.
- [5]COLEMAN R L,OZA A M,LORUSSO D,et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,390(10106):1949-1961.
- [6]COLEMAN R L,FLEMING G F,BRADY M F,et al.Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer[J].N Engl J Med,2019,381(25):2403-2415.
- [7]RAY-COQUARD I,PAUTIER P,PIGNATA S,et al.Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer[J].N Engl J Med,2019,381(25):2416-2428.
- [8]MORICE P M,LEARY A,DOLLADILLE C,et al.Myelodys-plastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors:a safety meta-analysis of random-ised controlled trials and a retrospective study of the WHO pharmacovigilance database[J].Lancet Haematol,2021,8(2):e122-e134.
- [9]BOLTON K L,MOUKARZEL L A,PTASHKIN R,et al.The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis[J].J Clin Oncol,2020,38(15_suppl):1513-1513.
- [10]SHORT N J,RYTTING M E,CORTES J E.Acute myeloid leukaemia[J].Lancet,2018,392(10147):593-606.